Open Label Phase IIa Trial Evaluating the Effect and Safety of Transplantation of Fecal Microbiota in Children With Autism Spectrum Disorders and Gastrointestinal Symptoms
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: FMT Protocol.
- Who it may be relevant to
- Registry conditions: Autism Spectrum Disorder, Fecal Microbiota Transplantation (FMT). Basic parameters: 36 months — 72 months · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Proof of Concept Study : Open Label Phase IIa Trial Evaluating the Effect and Safety of Transplantation of Fecal Microbiota in Children With Autism Spectrum Disorders and Gastrointestinal Symptoms
Overview
Autism Spectrum Disorders (ASD), affect approximately 1% of the general population and are characterized by impairments in social communication associated with repetitive/stereotyped behaviors. Approximately one-third of these patients display gastrointestinal (GI) symptoms, and a growing number of studies suggest abnormalities of gut microbiota in ASD. Gut microbiota and the brain interact through complex pathways. Preliminary evidence in adults with ASD suggests that modulation of the gut microbiota by probiotics and/or prebiotics and more recently by fecal microbiota transplantation could improve GI symptoms but also socio-communication deficit, with persistent improvement at year 2.
Detailed description
1. Screening :
Screening will be done in ASD units of child psychiatry departments of Robert Debré 2. Information of patients and their families Information will be delivered in the child psychiatry department of Robert Debré hospital. 3. Inclusion Consent will be collected in CIC of Robert Debré hospital during the initial visit by child psychiatrist 7 to 15 days after information from the patient's family. 4. Patient follow-up during trial Initial visit: for parents and patient information. Further visits (W4, W18, W24, M12): treatment administrations will be done at the CIC. Subjects will be evaluated on efficacy and safety and acceptability. Stool, urine and blood samples will be collected.
Phone visits (W11 and M9): Safety and the Acceptability questionnaire (parents) will be evaluated. 5. Products: donor and transplant preparation 6. Same administration schedule in FMT
* D1 to D4: Vancomycin (10mg/kg, 4 times a day). 1st dose in the CIC, the 3 others at home * D4: Picoprep® treatment at home * D5: First FMT using rectal enema (100ml = 25g of stool from donor) using Foley probe (rectal administration) in CIC * D12: Second FMT using rectal enema (100ml = 25g of stool from donor) using Foley probe (rectal administration) in CIC * D19: Third FMT using rectal enema (100ml = 25g of stool from donor) using Foley probe (rectal administration) in CIC
Interventions
- Drug FMT Protocol
FMT protocol Samples (urine, blood, stool) collection Psychological examination Pediatric quality of life Scale Bristol Stool form Scale
Primary outcome measures
- Score of the Gastrointestinal Symptoms Rating Scale (GSRS) [Time frame: Week 18]
Secondary outcome measures (4)
- Score of Vineland Adaptative Behavior Composite 3 scale [Time frame: Day 0, Week 4, Week 18, Week 24, Month 12]
- Score of Pediatric Adverse Event Rating Scale [Time frame: Day 0, Day 5, Week 4, Week 18, Week 24, Month 12]
- Tolerability: Score of bristol Stool form [Time frame: Day 0, Week 4, Week 18, Week 24, Month12]
- Score of Pediatric Quality of Life Inventory [Time frame: Day 0, Week 18, Month 12]
Eligibility criteria
Inclusion criteria
- ASD diagnosis based on DSM-5 criteria
- Gastrointestinal symptoms: at least a score of 5 on 1 of the 5 GSRS domains (diarrhea, abdominal pain, constipation, indigestion, reflux) for over a period of 1 year or more
- Age between 36 and 72 months
- Consent from all legal guardians
- Social insurance affiliation
Exclusion criteria
- Severe intellectual deficit (IQ<30) or another uncontrolled comorbidity (e.g. epilepsy)
- Recent change in ASD global care (cognitive behavioral therapy 6 weeks before inclusion)
- Actual or past psychotropic medication
- Contraindications to colon preparation (Picoprep®) and/or to Meopa)
- Severe or uncontrolled gastrointestinal symptoms (e.g. urgent treatment needed)
- Undernutrition (age related BMI < 3rd percentile)
- Inflammatory bowel disease
- Exclusive diet (gluten- or sugar-free)
- Rectal enema contraindication
- Antibiotic or antifungal therapy 3 months before inclusion
- Probiotics 2 months before inclusion or FMT 12 months before inclusion
- Vancomycin or Picoprep® or Meopa (including excipients) known allergy or intolerance Experimental therapeutic trial participation 3 months before inclusion
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
France · 1 center
- Robert Debré Hospital — Paris
Identifiers
NCT: NCT07105267 · APHP241418 · 2025-520539-17-00